Diagnostics and modern treatment of migraine: what can a general practitioner do?
https://doi.org/10.33667/2078-5631-2021-14-13-18
Abstract
The article focuses on the basic principles of diagnosis and treatment of migraine at the stage of primary health care. The diagnostic criteria of migraine, common diagnostic errors and alarming symptoms that are indications for instrumental investigations are given. The main treatment strategies of migraine are described: behavioral therapy, attack relief, and preventive therapy. Special attention is being paid to the treatment of a migraine attack, depending on its severity, including the features of the use of simple analgesics and triptans – specific drugs that have a pathogenetic antimigrenous effect. The principles of the use of tryptans that provide a high effect of relieving a migraine attack are being listed. The advantages of eletriptan as a last‑generation triptan, which is highly effective in relieving migraine attacks and is safer than other drugs in this class, are highlighted. Among the modern classes of drugs that have an evidence base in migraine prevention, those that can be successfully used by general practitioners are indicated.
About the Author
V. V. Osipova
Scientific and Practical Psychoneurological Centre n.a. Z. P. Solovyov; University Headache Clinic Co.
Russian Federation
Russian Federation
Osipova Vera V., PhD Med, leading researcher
Moscow
References
1. The International Classification of Headache Disorders, 3rd edition (ICHD 3). Ceph alalgia. 2018; 38 (1): 1–211.
2. Ayzenberg I., Katsarava Z., Sborowski A., Chernysh M., Osipova V., Tabeeva G., Yakh no N., Steiner T.J. The prevalence of primary headache disorders in Russia: A coun trywide survey. Cephalalgia. 2012; 32 (5): 373–381. DOI: 10.1177/0333102412438977
3. Glembotskaya G.T., Kozub O.V. Pharmacoeconomic evaluation of the ‘burden’ of migraine in the Russian Federation. Clinical pharmacology and therapy. 2013; 22 (2): 83–86. (In Russ.)
4. Katsarava Z., Buse D.C., Manack A.N., Lipton R.B. Defining the differences between episodic migraine and chronic migraine. Current Pain and Headache Reports. 2012; 16 (1): 86–92. DOI: 10.1007/s11916-011-0233-z.
5. Artemenko A.R., Kurenkov A.L., Belomestova K.V. Principles of interviewing in the diagnosis of chronic migraine. Journal of Neurology and Psychiatry n.a. S.S. Korsakov. 2014; 9: 81–87. (In Russ.)
6. Tabeeva G.R., Yakhno N.N. Migraine. M .: GEOTAR Media, 2011; 622 p
7. Osipova V.V., Tabeeva G.R. Primary headaches: diagnostics, clinic, therapy: A Practical Guide. М.: Publisher Medical News Agency, 2014. 336 p. (In Russ.)
8. Osipova V.V. Migraine and tension type headache. In: Clinical guidelines. Neurology and Neurosurgery / eds. E.I. Gusev, A.N. Konovalov. 2nd ed., Revised. and ext. M.: GEOTAR Media, 2015. 424p. (In Russ.)
9. Steiner T.J., MacGregor E.A., Davies P.T.G. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension type, cluster and medication overuse headache. British Association for the Study of Headache, 3rd edn. 2007: 1–523.
10. Osipova V. V., Azimova Y. E., Tabeeva G. R., Tarasova S. V., Amelin A. V., Kutse melov I.B., Moldoveanu I.V., Odobesku S.S., Naumova G.I. Diagnosing headaches in Russia and countries of the former Soviet Union: state of the problem and its solutions. Annals of clinical and experimental neurology. 2012; 6 (2): 16–21. (In Russ.)
11. Mitsikostas D., Ashina M., Craven A. et al. EHF committee. European headache federation consensus on technical investigation for primary headache disorders. J. Headache Pain. 2015; 17: 5.
12. American Academy of Neurology. The utility of neuroimaging in the evaluation of headache in patients with normal neurological examinations. Neurology. 1994; 44: 1353–1354.
13. Sarchielli P., Pedini M., Coppola F. et al. Practice parameter: evidence based guidelines for migraine headache (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55 (6): 754–762.
14. Kruit M.C., van Buchem M.A., Launer L.J., Terwindt G.M., Ferrari M.D. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: The population based MRI CAMERA study. Cephalalgia. 2010; 30: 129–136. DOI: 10.1111/j.1468-2982.2009.01904.x.
15. Koreshkina M.I., Chalikov A.D., Nazinkina Y.V., Osipova V.V., Amelin A.V., Kosmacheva E.A. The study of cerebral blood flow using the high field MRI perfusion during an attack of migraine with aura. Epilepsy and paroxysmal states. 2012; 4 (4): 12–17. (In Russ.)
16. Bendtsen L., Birk S., Kasch H., Aegidius K., Sørensen P.S., Thomsen L.L., Poulsen L., Rasmussen M. J., Kruuse C., Jensen R. Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012. The Journal of Headache and Pain. 2012; 13 (S1): 1–29. DOI: 10.1007/s10194-011-0402-9.
17. Osipova V.V., Filatova E.G., Artemenko A.R. et al. Diagnostics and treatment of migraine: recommendations of Russian experts. Journal of Neurology and Psychiatry n.a. Korsakov 2017; 2: 28–42.
18. Kindelan Calvo P, Gil Martínez A., Paris Alemany A. et al. Effectiveness of therapeutic patient education for adults with migraine. A systematic review and meta analysis of randomized controlled trials. Pain Med. 2014; 15 (9): 1619–1636.
19. Mett A., Tfelt Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr. Opin. Neurol. 2008; 21 (3): 331–337.
20. Orr S.L., Aube´ M., Becker W.J. et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015; 35: 271.
21. Cameron C., Kelly S., Hsieh S.C. et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta Analysis. Headache. 2015; 55 (Suppl 4): 221–235.
22. Ferrari M. D., Goadsby P. J., Roon K. I., Lipton R. B. Triptans (serotonin, 5 HT1B/1D agonists) in migraine: detailed results and methods of a meta analysis of 53 trials. Cephalalgia. 2002; 22: 633–658.
23. Colman I., Brown M.D., Innes G.D. et al. Parenteral metoclopramide for acute migraine: meta analysis of randomised controlled trials. BMJ. 2004; 329 (7479): 1369–1373.
24. Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E, Goadsby PJ. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta analysis. Cephalalgia. 2014 Apr; 34 (4): 258–67. DOI: 10.1177/0333102413508661. Epub 2013 Oct 9. PMID: 24108308.
25. Diener et al. The 40 mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg European Journal of Neurology 2004, 11: 125–13.
26. Filatova E.G. Treatment of migraine attacks. Russian Medical Journal. 2013; 21 (16): 862–865. (In Russ.)
27. Amelin A.V. NSAIDs and triptans for migraine: separately or together? Breast cancer. Neurology; T. 19, No. 2, 2011; 3–7 p.
28. Scholpp J., Shellenberg R., Moeckesch B., et al. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia. 2004. V. 24. P. 918–924.
29. Filatova E.G., Amelin A.V., Tabeeva G.R. Ready – the first Russian multicenter study of the efficacy of the drug relpaks (eletriptan) for the treatment of migraine. Treatment of Nervous Diseases. 2006; 2: 19–22. (In Russ.).
30. Olesen J., Diener H.C., Schoenen J., Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. 2004; 11: 671–677.
31. Sheftell F, Ryan R, Pitman V; Eletriptan Steering Committee. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, dou ble blind, placebo controlled study conducted in the United States. Headache. 2003; 43: 202–213.
32. Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache. 2003; 43: 214–222.
33. Steiner TJ, Diener H C, MacGregor EA, et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia. 2003; 23: 942–952.
34. Canadian Headache Society Guideline for Migraine Prophylaxis. The Canadian Journal of Neurological Sciences. 2012; 39 (S2): i 63. DOI: 10.1017/s0317167100015109.
35. Jackson J.L., Cogbill E., Santana Davila R. et al. Comparative effectiveness me ta analysis of drugs for the pophylaxis of migraine headache. PLoS One. 2015; 10 (7): e0130733.
36. He A., Song D., Zhang L., Li C. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network meta analysis. J. Headache Pain. 2017; 18 (1): 26.
37. Kangasniemi P., Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double blind study. Cephalalgia. 1984; 4: 91–96.
38. Chronicle E.P., Mulleners W.M. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst. Rev. 2016; 5: CD003226.
39. Jackson J.L., Shimeall W., Sessums L., et al. Tricyclic antidepressants and headaches: systematic review and meta analysis. BMJ. 2010; 341: c5222.
40. Negro A., Curto M., Lionetto L., Martelletti P. A two years open label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real world experience. J Headache Pain. 2015; 17: 1.
41. Cady R.K., Schreiber C.P., Porter J.A. et al. A multi center double blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011; 51 (1): 21–32.
42. Dodick D.W., Ashina M., Brandes J.L. et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018; 38: 1026–1037.
43. Dodick DW et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial. JAMA. 2018; 319 (19): 1999–2008.
44. Dekker F., Neven A.K., Andriesse B. et al. Prophylactic treatment of migraine by GPs: a qualitative study. Br.J. Gen. Pract. 2012; 62 (597): 268–274.
Review
For citations:
Osipova V.V. Diagnostics and modern treatment of migraine: what can a general practitioner do? Medical alphabet. 2021;(14):13-18. (In Russ.) https://doi.org/10.33667/2078-5631-2021-14-13-18
Views: 376
Email this article 